Biopharmaceuticals: An overview

Thai Journal of Pharmaceutical Sciences

Volumn 34, Issue 1, 2010, Pages 1-19

  Sekhon, Bhupinder Singh ^a  

^a Punjab College of Technical Education   (India)

Author keywords

Biopharmaceuticals; Bioprocessing; Biotechnology; Transgenics

Indexed keywords

ABATACEPT; ADALIMUMAB; BETA INTERFERON; BLOOD CLOTTING FACTOR; COMPLEMENTARY RNA; CYTOKINE; EPRATUZUMAB; ETANERCEPT; GLATIRAMER; GLUCOSYLCERAMIDASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INFLAMMASOME; INFLIXIMAB; INTERFERON BETA SERINE; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 3; MACROGOL; MONOCLONAL ANTIBODY; NATALIZUMAB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; POLYPEPTIDE ANTIBIOTIC AGENT; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; TOCILIZUMAB; TRASTUZUMAB; UNINDEXED DRUG; VACCINE;

BIOPROCESS; BREAST CANCER; CELL THERAPY; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CHRONIC MYELOID LEUKEMIA; CRYSTALLIZATION; DRUG CLASSIFICATION; DRUG DESIGN; DRUG DETERMINATION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG ISOLATION; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG SAFETY; FEBRILE NEUTROPENIA; GAUCHER DISEASE; GENETIC ENGINEERING; GLYCOSYLATION; HUMAN; INTERMETHOD COMPARISON; MEMBRANE TECHNOLOGY; MULTIPLE SCLEROSIS; NONHUMAN; PEPTIDE SYNTHESIS; PHARMACEUTICAL ENGINEERING; RECOMBINANT DNA TECHNOLOGY; REVIEW; RHEUMATOID ARTHRITIS; TRANSGENE; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION;

EID: 77956260809     PISSN: 01254685     EISSN: 19054637     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. R. A. Rader. What is a biopharmaceutical? Part 1: (Bio) Technology-based definitions, BioExecutive International, 2005, pp. 60-65. Available from: http://www.biopharma.com/ terminology.html.
2. R. A. Rader. (Re) defining biopharmaceutical, Nat. Biotechnol. 26: 743-751 (2008).
3. A. S. Rathore, and H. Winkle. Quality by design for biopharmaceuticals, Nat. Biotechnol. 27: 26-34 (2009).
4. R. Dutton, and J. Scharer. Advanced Technologies in Biopharmaceutical Processing, Wiley-Blackwell, 2006.
5. Emerging technologies in biopharmaceuticals, Cited January 2006, Available from: http://www.witts.org/Innovation/ innovation_48_jan06/wista_innovation_feature.htm.
6. F. Locatelli, and S. Roger. Comparative testing and pharmacovigilance of biosimilars, Nephrol. Dial. Transplant. 21: v13-v16 (2006).
7. R. A. Rader. What is a generic biopharmaceutical? Biogeneric? Follow-on protein? Biosimilar? Follow-on biologic?, BioProcess International, 2007, pp. 28-38.
8. J. A. Lowe, and P. Jones. Biopharmaceuticals and the future of the pharmaceutical industry, Curr. Opin. Drug Discovery Dev. 10: 513-514 (2007).
9. G. Walsh. Biopharmaceuticals: Biochemistry and Biotechnology (2nd ed.), John Wiley & Sons, 2003.
10. Biopharmaceuticals: Current Market Dynamics & Future Outlook, AS Insights, Cited 1 May 2005, Report Code: ASI0505-5, 66 Pages. Available from: http://www.bioportfolio.com/ cgi-bin/acatalog/Biopharmaceuticals_Current_ Market_ Dynamics_Futur.html
11. Delivering New Biopharmaceutical Therapies: Challenges & Opportunities, PharmaVision, Cited January 2009, Available from: http://www.thepharmyard.com/shop/ product.php?xProd=2360.
12. R. Jefferis. Glycosylation as a strategy to improve antibodybased therapeutics, Nat. Rev. Drug Discovery. 8: 226-234 (2009).
13. D. J. A. Crommelin, G. Storm, R. Verrijk, L. de Leede, W. Jiskoot, and W E. Hennink. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs, Int. J. Pharm. 266: 3-16 (2003).
14. X. Hu, Q. Ma, and S. Zhang. Biopharmaceuticals in China, Biotechnol. J.†1: 1215-1224 (2006).
15. G. Walsh. Second-generation biopharmaceuticals, Eur. J. Pharm. Biopharm. 58: 185-196 (2004).
16. A. V. Gothoskar, and S. M. Khangaonkar. Biopharmaceutical classification of drugs, Pharm. Rev. 3: 1 (2005).
17. Cytokines, Cited 19 Feb 2006, Available from: http://www. microvet.arizona.edu/courses/MIC419/Tutorials/cytokines. html.
18. Biopharmaceuticals II. Core 218, Cited Spring 2007, Available from: http://www.agls.uidaho.edu/biotech_society/Lecture_ Presentations/Lecture17_BiopharmaceuticalsII.ppt
19. M. Fredric, and J. R. Steinberg. Biotech pharmaceuticals and biotherapy: An overview, J. Pharm. Pharm. Sci. 1: 48-59 (1998).
20. R. D. Sindelar. Pharmaceutical biotechnology. In: W O. Foyes, T. L. Lemke, and D. A. Williams, (eds.), Principles of Medicinal Chemistry (4th ed.), Williams & Wilkins, PA, 1995, p. 637.
21. M. Fishman, and J. Seigne. Immunotherapy of metastic renal cell cancer: Variants of IL-2 and IFN, Cancer Control 9: (2002).
22. Y. Kannan, M. Moriyama, T. Sugano, J. Yamate, M. Kuwamura, A. Kagaya, and Y. Kiso. Neurotrophic action of interleukin 3 and granulocyte-macrophage colony-stimulating factor on murine sympathetic neurons, Neuroimmuno modulat. 8: 132-141 (2000).
23. A. Zambrano, C. Otth, L. Mujica, I. I. Concha, and R. B Maccioni. Interleukin-3 prevents neuronal death induced by amyloid peptide, BMC Neurosci. 8: 82 (2007).
24. E. Dunn, J. E. Sims, M. J. Nicklin, L. and A. OûNeill. Annotating genes with potential roles in the immune system: six new members of the IL-1 family, Trends Immunol. 22: 533-536 (2001).
25. T. T. Pizarro, and F. Cominelli. Cloning IL-1 and the birth of a new era in cytokine biology, J. Immunol. 178: 5411-5412 (2007).
26. J. E. Sims, M. J. Nicklin, J. F. Bazan, J. L. Barton, S. J. Busfield, J. E. Ford, R. A. Kastelein, S. Kumar, H. Lin, J. J. Mulero, J. Pan, Y. Pan, D. E. Smith, and P. R. Young. A new nomenclature for IL-1-family genes, Trends Immunol. 22: 536-537 (2001).
27. A. Gaestel, A. Kotlyarov, and M. Kracht. Targeting innate immunity protein kinase signalling in inflammation, Nat.Rev. Drug Discovery 8: 480-99 (2009).
28. C. A. Dinarello. Immunological and inflammatory functions of the interleukin-1 family, Annu. Rev. Immunol. 27: 519- 550 (2009).
29. F. Martinon, A. Mayor, and J. Tschopp. The inflammasomes: guardians of the body, Annu. Rev. Immunol. 27: 229-265 (2009).
30. S. Farasat, I. Aksentijevich, and J. R. Toro. Autoinflammatory diseases: clinical and genetic advances, Arch. Dermatol. 144: 392-402 (2008).
31. P. E. Auron, A. C. Webb, L. J. Rosenwasser, S. F. Mucci, A. Rich, S. M. Wolff, and C. A. Dinarello. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA, Proc. Natl. Acad. Sci. U.S.A. 81: 7907-7911 (1984).
32. C. A. Dinarello. Biologic basis for interleukin-1 in disease, Blood 87: 2095-2147 (1996).
33. A. Weber, P. Wasiliew, and M. Kracht. Interleukin-1 (IL-1) Pathway. Sci. Signal. 3: cm1 (2010).
34. E. U. Sumer, B. C. Sondergaard, S. H. Madsen, P. Qvist, and M. A. Qvist. P85 Interleukin-1 alpha in comparison to interleukin-1 beta is a more potent stimulator of aggrecanase mediated aggrecan degradation in human articular cartilage, Osteoarth. Cartilage 14 (Suppl. 2): S58 (2006).
35. L. D. Church, and M.l F. McDermott. Rilonacept in cryopyrinassociated periodic syndromes: the beginning of longeracting interleukin-1 antagonism, Nat. Rev. Rheumatol. 5: 14-15 (2009).
36. L. Franchi, T. Eigenbrod, R. Muñoz-Planillo, and G. Nuñez. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis, Nat. Immunol. 10: 241-247 (2009).
37. L. D. Church, G. P. Cook, and M. F. McDermott. Primer: inflammasomes and interleukin 1 â in inflammatory disorders, Nat. Clin. Pract. Rheumatol. 4: 34-42 (2008).
38. Biopharmaceuticals II. Available from: http://www.agls.uidaho.edu/ biotech/Lecture17_BiopharmaceuticalsII.ppt.
39. E. W. Davie, and K. Fujikawa. Basic mechanisms in blood coagulation, Annu. Rev. Biochem. 44: 799-829 (1975).
40. Clotting factor replacement therapy for hemophilia, Cited 9 December 2009. Available from: http://www.nhlbi.nih.gov/ health/dci/Diseases/hemophilia/hemophilia_treat.
41. A. Kaul, S. Stauffer, C. Berger, T. Pertel, J. Schmitt, S. Kallis, M. Z. Lopez, V. Lohmann, J. Luban, and R. Bartenschlager. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics, PLoS Pathog. 5(8): e1000546 (2009).
42. W. A. Marasco, and J. Sui. The growth and potential of human antiviral monoclonal antibody therapeutics, Nat. Biotechnol. 25:1421-1434 (2007).
43. Stem cell therapies today. Available from: http://learn. genetics.utah.edu/content/tech/stemcells/sctoday.
44. C. Mason, and E. Manzotti. Stem cell nations working together for a stem cell world, Regener. Med. 5: 1-4 (2010).
45. I. L. Weissman. Stem cells: units of development, units of regeneration, and units in evolution, Cell 100: 157-689 (2000). Cited in G. C. Gurtner, M. J. Callaghan, and M. T. Longaker. Progress and potential for regenerative medicine, Ann. Rev. Med. 58: 299-312 (2007).
46. I. Singec, R. Jandial, A. Crain, G. Nikkhah, and E. Y. Snyder. The leading edge of stem cell therapeutics, Annu. Rev. Med. 58: 313-328 (2007).
47. E. R. Rayburn, H. Wang, and R. Zhang. Antisense-based cancer therapeutics: are we there yet?, Expert. Opin. Emerg. Drugs 11: 337-352 (2006).
48. P. A. Morcos. Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos, Biochem. Biophys. Res. Commun. 358: 521-527 (2007).
49. R. Malik, and I. Roy. Design and development of antisense drugs, Expert Opin. Drug Discovery 3: 1189-1207 (2008).
50. X. Zhao, F. Pan, C. M Holt, A. L. Lewis, and J. R. Lu. Controlled delivery of antisense oligonucleotides: a brief review of current strategies, Expert Opin. Drug Del. 6: 673-686 (2009).
51. P. C. F. Oyston, M. A. Fox, S. J. Richards, and G. C. Clark. Novel peptide therapeutics for treatment of infections, J. Med Microbiol. 58: 977-987 (2009).
52. Interest grows in peptide therapeutics as production techniques improve, Cited 22 Jan 2010. Available from: http://www.scientistlive.com/European-Science-News/ Drug_Discovery/Interest_grows_in_peptide_therapeutics_as_production_techniques_improve/13855.
53. D. P. McGregor. Discovering and improving novel peptide therapeutics, Curr. Opin. Pharmacol. 8: 616-619 (2008).
54. S. M. Ryan, G. Mantovani, X. Wang, D. M. Haddleton, and D. J. Brayden. Advances in PEGylation of important biotech molecules: delivery aspects, Expert Opin. Drug Del. 5: 371-383 (2008).
55. D. Filpula, and H. Zhao. Releasable PEGylation of proteins with customized linkers, Adv. Drug Deliv. Rev. 60: 29-49 (2008).
56. F. M. Veronese, and G. Pasut. PEGylation, successful approach to drug delivery, Drug Discovery Today 10: 1451-1458 (2005).
57. S. Morar, J. L. Schrimsher, and M. D. Chavez. PEGylation of proteins: A structural approach, Biopharm. Internat. 19: 34 (2006).
58. I. Dews. Development of biosimilar drugs, Clinical Research Focus 17: 5-10 (2006).
59. H. Schellekens. Follow-on biologics: challenges of the next generation, Nephrol. Dial Transaplant 20 (Suppl. 4): iv31-36 (2005).
60. H. Schellekens. Biosimilar therapeutics-what do we need to consider? Nephrol. Dial Transaplant Plus 2: i27-i36 (2009).
61. S. D. Roger. Biosimilars: how similar or dissimilar are they? Nephrology((Carlton) 11: 341-346 (2006).
62. R. A. Judge, E. L. Forsythe, and M.L. Pusey. The effect of protein impurities on lysozyme crystal growth, Biotechnol. Bioeng. 59: 776-785 (1998).
63. A. McCook. Manufacturing on a grand scale, The Scientist 19: 34 (2005).
64. D. W. Zhu, A. Garneau, M. Mazumdar, M. Zhou, G. I. Xu, and S. X. Lin. Attempts to rationalize protein crystallization using relative crystallizability, J. Struct. Biol. 154: 297-302 (2006).
65. E. W. St. Clair, and R.M. McCallum. Coganûs syndrome, Curr. Opin. Rheumatol. 1: 47-52 (1999).
66. B. Shenoy, Y. Wang, W. Shan, and A.L. Margolin. Stability of crystalline proteins, Biotechnol. Bioeng. 73: 358-369 (2001).
67. E. Lipp. Protein crystallization in pharma research-Refinements of the technology are taking place very quickly, Gene Eng. Biotechnol. News 26: 15 (2006).
68. A. Basu, J. K. Krady, and S. W. Levison. Interleukin-1: A master regulator of neuroinflammation, J. Neurosci. Res. 78: 151-156 (2004).
69. D. Vivares, S. Veesler, J. P. Astier, and F. Bonneté. polymorphism of urate oxidase in PEG solutions, Cryst. Growth Des. 6: 287-292 (2006).
70. S. K. Basu, C. P. Govardhan, C. W. Jung, and A. L. Margolin. Protein crystals for the delivery of biopharmaceuticals, Expert Opin. Biol. Ther. 4: 301-317 (2004).
71. R. R Rustandi, M. W. Washabaugh, and Y. Wang. Applications of CE SDS gel in development of biopharmaceutical antibody-based products, Electrophoresis 29: 3612-3620 (2008).
72. P. Ball. The Power of Proteomics in Biopharmaceutical Drug Development. pp.112-115, Cited 4 September 2006. Available from: http://www.edenbiodesign.com/articles- 2007. php.
73. E. L. Decker, and R. Reski. Current achievements in the production of complex biopharmaceuticals with moss bioreactor, Bioprocess. Biosyst. Eng. 31: 3-9 (2008).
74. S. Behme. Manufacturing of Pharmaceutical Proteins: From Technology to Economy, Wiley, 2009.
75. J. X. Zhou, T. Tressel, T. Hong, F. Li, X.Yang, and B. Lee. Advances in large-scale biopharmaceutical manufacturing and scale-up production (2nd ed.), ASM Press [American Society for Microbiology] and BioPlan Associates, 2007.
76. KnÍ blein J. (ed.). Modern Biopharmaceuticals, Wiley-VCH, 2008.
77. A. L. Demain, and P. Vaishnav. Production of recombinant proteins by microbes and higher organisms, Biotechnol. Adv. 27: 297-306 (2009).
78. R.J. Solá, and K. Griebenow. Effects of glycosylation on the stability of protein pharmaceuticals, J. Pharm. Sci. 98: 1223-1245 (2009).
79. D. Ellison. Edin Design. Biopharmaceutical Development and Clinical Manufacturing, Cited 9 June 2008, Available from: http://www.bionow.co.uk/uploads/documents/jun_08/bionow_1213884750_Dr_Derek_Ellison_Eden_Biodesig.pdf
80. Eden Biodesign- Pharmaceuticals PharmaTech. Available from: http://www.jazdlifesciences.com/pharmatech/company/ Eden-Biodesign.htm? supplierId=30001718.
81. A practical guide to biopharmaceutical manufacturing. Available from: http://www.researchandmarkets.com/reports/ 577407.
82. K. E. Avis, and V. L. Wu (eds). Biotechnology and Biopharmaceutical Manufacturing, Processing, and Preservation (Drug Manufacturing Technology Series, Vol 2), CRC, 1996.
83. Strategic analysis of downstream processing in biopharmaceutical production. Available from: http://www. researchandmarkets.com/reports/358276.
84. B. Kelley. Very large scale monoclonal antibody purification: The case for conventional unit operations, Biotechnol. Prog. 23: 995-1008 (2007).
85. Characterization of biopharmaceuticals. Available from: http:/ /www.m-scan.com/analytical-services-consultancy/lifesciences- and-pharmaceutical-analysis/characterizationof- biopharmaceuticals.
86. C. E. Bobst, R. R. Abzalimov, D. Houde M. Kloczewiak, R. Mhatre, S. A. Berkowitz, and I. A. Kaltashov. Detection and characterization of altered conformations of protein pharmaceuticals using complementary mass spectrometrybased approaches, Anal. Chem. 80: 7473-7481 (2008).
87. N. L. M. Callewaert, W.Vervecken, K.J. M.De Pourcq, S. C. J. Geysens, and M. Guerfal. Glycosylation of molecules, USPTO Application #: 20090069232. 03/12/09 Available from; http://www.freshpatents.com/-dt20090312ptan20090069232.php.
88. J. Liu, J. D. Andya,†and S. J. Shire. Critical review of analytical ultracentrifugation and field flow fractionation methods for measuring protein aggregation, AAPS Journal 8: E580-E589 (2006).
89. R. Tremblay, D. Wang, A. M. Jevnikar, and S. Ma. Tobacco, a highly efficient green bioreactor for production of therapeutic proteins, Biotechnol. Adv. 28: 214-221 (2010).
90. P. Mudhar. Biopharmaceuticals: Insight into todayûs market and a look to the future Pharmaceutical Technology Europe. Cited 1 September 2006; In: C. Boi, and G. C. Sarti. Development and characterization of affinity membranes for immunoglobulin purification, Sep. Sci. Technol. 42: 2987-3001 (2007).
91. The future battle between biopharmaceuticals and biogenerics, Cited 30 October 2003. Available from: http:// www. marketresearch.com/product/display.asp?productid=943022.
92. D. Simon, I. Roger, and A. Mikhail. Biosimilars: opportunity or cause for concern? J. Pharm. Pharm. Sci. 10: 405-410 (2007).
93. Biosimilars: a viable market-but when?, Cited 12 September 2008, Available from: https://www.espicom.com/ Prodcat.nsf/Search/00000012?OpenDocument.
94. R. van Reis, and A. Zydney. Bioprocess membrane technology, J. Membrane Sci. 297: 16-50 (2007).
95. P. Pattnaik, I. Louis, and M.S. Mahadevan. Use of membrane technology in the bioprocessing of therapeutic proteins from inclusion bodies of E. coli, Bioprocess Int. 7: 54-62 (2009).
96. L. Crossley, T. Mayes, L. Steele, and M. Heng. New technologies in biopharmaceutical downstream processing, In: R. L. Dutton, and J. M. Scharer (eds). Advanced Technologies in Biopharmaceutical Processing, Wiley- Blackwell, 2007.
97. R. Ghosh. Biopharmaceutical separations by ultrafiltration, Chapter 15, In: N. N. Li (ed.). Advanced Membrane Technology and Applications, John Wiley & Sons, 2008.
98. P. Klaus-Viktor, and P. N. Suzana (eds.). Membrane Technology, Volume 1: Membranes for Life Sciences, Wiley-VCH, Weinheim, 2007.
99. X. Liu, M. Collins, N. Fraud, J. Campbell, I. Lowenstein, K. M. Lacki, and A. Rathore. Upcoming technologies to facilitate more efficient biologics manufacturing, Pharm. Technol. Europe 21: 4 (2009).
100. Implementation of membrane technology in antibody large-scale purification, In Advances in Large-Scale Biopharmaceutical Manufacturing and Scale-Up Production (2nd ed.), ASM Press (American Society for Microbiology) and BioPlan Associates, 2007. Available from: http://www.bioplanassociates.com/asm/Abst22.html.
101. P. Rose. Biopharmaceutical technology: cell harvestinggetting cultural. Filtr. Sep. 45: 29-31 (2008).
102. Advances in biotechnology cause an overhaul of processes in the pharmaceuticals industry, Cited 24 Jun 2005. Available from: http://cleanroomsfaq.blogspot.com/2008/ 05/disposable-biopharmaceutical.html.
103. W. Ding, and J. Martin. Implementing single-use technology In biopharmaceutical manufacturing. Available from: http:// www.bioresearchonline.com/download.mvc/Implementing- Single-Use-Technology-In-0001.
104. A. Sinclair, L. Leveen, M. Monge, J. Lim, and S. Cox. The environmental impact of disposable technologies, Biopharm Intl. Supplement Nov. 2008, pp. 4-15. Available from:http:// biopharminternational.findpharma.com//Disposables/The-Environmental-Impact-of-Disposable/566014.
105. H. Pora, and B. Rawlings. Managing solid waste from single-use systems in biopharmaceutical manufacturing, Bioprocess Internat. Jan. 2009, pp.18-25. Available from: http:// www. bioresearchonline.com//Managing-Solid-Waste-From- Single-Use-Systems-0003.
106. M. E. Ultee Single-use technologies in biopharmaceutical manufacturing from cell culture through aseptic filling. IBC Conference on Antibody Development and Manufacturing, Carlsbad, CA, 2/28-3/2/07. Cited 17 Jun 2009 Available from: http://www.pharmpro.com/ShowPR~PUBCODE~021~ ACCT~0013924~ISSUE~0903~RELTY.
107. C. Valle. Biotechnology drugs: Integrated single-use technologies for biopharmaceuticals, Filtr. Sep. 46:18-21 (2009).
108. G. Hodge. Disposable components enable a new approach to biopharmaceutical manufacturing, Biopharm. Int. 17: 38- 48 (2004).
109. D. Pendlebury. The use of disposable systems in the manufacture of biopharmaceuticals, Bioproces. J. 4: 59-63 (2005).
110. Extractables and Leachables Subcommittee of the Bio-process Systems Alliance. Recommendations for extractables and leachable testing. Part 1. BioProcess International December 2007, pp. 36-44. Available from: http:// www.bpsalliance.org/BPSAPart1ELGuide1207.pdf; Recommendations for extractables and leachable testing. Part 2. January 2008, pp. 36-44, Available from: http:// www.bpsalliance.org/BPSAPart2ELGuide0108.pdf.
111. J. S. Wilson. A fully disposable monoclonal antibody manufacturing train, BioProcess International Supplement Series-Disposables, Cited June 2006, pp. 34-36. Available from: http://www.bioresearchonline.com//bioprocessintl.html.
112. E. S. Langer, and B. J. Price. Disposables: Biopharmaceutical disposables as a disruptive future technology, BioPharm International, Cited 1 Jun 2007. Available from: http:// www. bioplanassociates.com//Bp0607_DisposablesAsDisruptive_ Jun07.pdf.
113. H. Takahashi, D. Letourneur, and D.W. Grainger. Delivery of large biopharmaceuticals from cardiovascular stents: a review, Biomacromolecules 8: 3281-3293 (2007).
114. S. P. Venkateshan, S. Sidhu, S. Malhotra, and P. Pandhi. Efficacy of biologicals in the treatment of rheumatoid arthritis. a meta-analysis, Pharmacol. 83: 1-9 (2009).
115. P. T. Fan, and K. H. Leong. The use of biological agents in the treatment of rheumatoid arthritis, Ann. Acad. Med. Singapore 36: 128-134 (2007).
116. B. Baslund, and K. Bendtzen. Biopharmaceuticals in the treatment of rheumatoid arthritis, Ugeskr Laeger 170: 2108- 2110 (2008).
117. Developments in Biologicals Vol.118: PDA/EMEA European Virus Safety Forum, Langen, 2003.
118. K. Brorson, L. Norling, E. Hamilton, S. Lute, K. Lee, S. Curtis, and Y. Xu. Current and future approaches to ensure the viral safety of biopharmaceuticals, Dev. Biol. (Basel), 118: 17-29 (2004).
119. S.R. Schmidt. Fusion-proteins as biopharmaceuticalsapplications and challenges, Curr. Opin. Drug Discovery Dev. 12: 284-295 (2009).
120. M. Hamidi, A. Zarrin, M. Foroozesh, and S. Mohammadi- Samani. Applications of carrier erythrocytes in delivery of biopharmaceuticals, J. Control. Release 118: 145-160 (2007).
121. M. Matasci, D.L. Hacker, L. Baldi, and F.M. Wurm. Recombinant therapeutic protein production in cultivated mammalian cells: current status and future prospects, Drug Discovery Today: Technologies 5: e37-e42 (2008). †
122. T. L. Potgieter, M. Cukan, J. E. Drummond, N. R. Houston- Cummings, Y. Jiang, F. Li, H. Lynaugh, M. Mallem, T.W. McKelvey, T. Mitchell, A. Nylen, A. Rittenhour, T. A. Stadheim, D. Zha, and M. dûAnjou. Production of monoclonal antibodies by glycoengineered Pichia pastoris, J. Biotechnol. 139: 318- 325 (2009).
123. Y. Han, S. Liu, J. Ho, M. K. Danquah, and G. M. Forde. Using DNA as a drug-Bioprocessing and delivery strategies, Chem. Eng. Res. Design 87: 343-348 (2009).
124. S. C. Wu. RNA interference technology to improve recombinant protein production in Chinese hamster ovary cells, Biotechnol. Adv. 27: 417-422 (2009).
125. A.M. Azevedo, P.A.J. Rosa, I.F. Ferreira, and M.R. Aires- Barros. Chromatography-free recovery of biopharmaceuticals through aqueous two-phase processing, Trends Biotechnol. 27: 240-247 (2009).
126. J. L. Teillaud. What is biotherapy? The monoclonal antibody case, Presse. Med. 38: 825-831 (2009).
127. G.D. L. Phillips, G. Li, D. L. Dugger, L. M. Crocker, K. L. Parsons, E. Mai, W. A. Blättler, J. M. Lambert, R. V. J. Chari, R. J. Lutz, W. L. T. Wong, F. S. Jacobson, H. Koeppen, R. H. Schwall, S. R. Kenkare-Mitra, S. D. Spencer, and M. X. Sliwkowski. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate, Cancer Res. 68: 9280 (2008).
128. W. A. Marasco, and J. Sui. The growth and potential of human antiviral monoclonal antibody therapeutics, Nat. Biotechnol. 25: 1421-1434 (2007).
129. C. R. Ill, and H. Dehghani. Risk reduction in biotherapeutic products, Curr. Opin. Drug Discovery Dev. 12: 296-304 (2009).
130. G. Sivakumar. Bioreactor technology: A novel industrial tool for high-tech production of bioactive molecules and biopharmaceuticals from plant roots, Biotechnol. J.†1: 1419- 1427 (2006).
131. Anemia, Pfizer, Cited 25 Feb 2009, Available from: pfizer.adam.com/content.aspx?productId=10&pid=10&gid.
132. H. Ehrenreich, D. Degner, J. Meller, M. Brines, M. Béhé, M. Hasselblatt, H. Woldt, P. Falkai, F. Knerlich, S. Jacob, N. von Ahsen, W. Maier, W. Brück, E. Rüther, A. Cerami, W. Becker, and A. L. Sirén. Erythropoietin: a candidate compound for neuroprotection in schizophrenia, Mol. psychiatry 9: 42-54 (2004).
133. A. L. Sirén, M. Fratelli, M. Brines, C. Goemans, S. Casagrande, P. Lewczuk, S. Keenan, C. Gleiter, C. Pasquali, A. Capobianco, T. Mennini, R. Heumann, A. Cerami, H. Ehrenreich, and P. Ghezzi. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress, Proc. Natl. Acad. Sci. U.S.A. 98: 4044-4049 (2001).
134. Z. A. Haroon, K. Amin, X. Jiang, and M. O. Arcasoy. A novel role for erythropoietin during fibrin-induced wound-healing response, Am. J. Pathol. 163: 993-1000 (2003).
135. L. F. Lopes, and C. E. Bacchi. Imatinib treatment for gastrointestinal stromal tumor (GIST), J. Cell. Mol. Med. (2009). [Epub ahead of print] DOI: 10.1111/j.1582-4934.2009. 00983.x.
136. B. Weinstock-Guttman, M. Ramanathan, and R. Zivadinov. Interferon-â treatment for relapsing multiple sclerosis, Exp. Opin. Biol. Ther. 8: 1435-1447 (2008).
137. J. M. Reicher. Monoclonal antibodies as innovative therapeutics, Curr. Pharm. Biotechnol. 9: 423-430 (2008).
138. M. Chartrain, and L. Chu Development and production of commercial therapeutic monoclonal antibodies in Mammalian cell expression systems: an overview of the current upstream technologies, Curr. Pharm. Biotechnol. 9: 447-467 (2008).
139. F. Di Pauli, T. Berger, and M. Reindl. Monoclonal antibodies in the treatment of multiple sclerosis, Curr. Med. Chem. 16: 4858-4868 (2009).
140. K. P. Johnson. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis, Neurologist. 13: 182-187 (2007).
141. M. I. Vasiliu, M. A. Petri, and A. N. Baer. Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares, J. Rheumatol. 33: 1878-1880 (2006).
142. R. Varki, E. Pequignot, M. C. Leavitt, A. Ferber, and W. K. Kraft. A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study, BMC Clin. Pharmacol. 9: 2 (2009).
143. J. Charrow. Enzyme replacement therapy for Gaucher disease, Expert Opin. Biol. Ther. 9:121-131 (2009).
144. D. Aviezer, E. Brill-Almon, Y. Shaaltiel, S. Hashmueli, D. Bartfeld, S. Mizrachi, Y. Liberman, A. Freeman, A. Zimran, and E. Galun. A plant-derived recombinant human glucocerebrosidase enzyme-a preclinical and phase I investigation, PLoS One 4: e4792 (2009).
145. Y. Ilan, D. Elstein, and A. Zimran. Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent, Immunol. Cell Biol. 87: 514-524 (2009).
146. P. K. Sharma, D. Hota, and P. Pandhi. Biologics in rheumatoid arthritis, J. Assoc. Physicians India 52: 231-236 (2004).
147. Biopharmaceutical developments-an emerging technology analysis (technical insights). Cited 24 Jun 2005. Available from: http://www.frost.com/prod/servlet/report-brochure.pag?id=D362-01-00-00-00